Valion Bio terminates CEO, appoints COO, secures $1.5M funding from 3i

Valion Bio, Inc.

CEO Michael K. Handley terminated effective Aug 16, 2026; Lisa Wolf appointed COO, remains CFO.
Letter Agreement with 3i, LP: $1.5M for 1,500 Series B Preferred at $1,000/share plus warrants.
Second closing of $1.5M for another 1,500 shares if definitive side letter executed by Aug 24, 2026.
Royalty Agreement: 5% of Velocity Bioworks gross revenue for 10 years to 3i and other purchasers.
Stockholders approved reverse stock split (1:5 to 1:50) at special meeting.

item 1.01 item 3.02 item 8.01 item 5.02 item 5.07 item 9.01

Featured in Daily 8-K Digest

Selected #10 for 2026-08-17. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.